Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

ORPH.L (ORPH) Share News

IN BRIEF: Open Orphan wins GBP5 million human challenge study pact

25th Mar 2022 14:10

Open Orphan PLC - London-based pharmaceutical services firm - Says its subsidiary, hVIVO, wins contract with a European biotechnology company for a human challenge study. The GBP5 million contract with a European biotech seeks to test hVIVO's intravenous antiviral candidate. The study on the respiratory syncytial virus is expected to commence this year. Revenue from the deal will be recognised across 2022 and 2023. Read More

IN BRIEF: Open Orphan expects to report profitable 2021 performance

8th Mar 2022 19:37

Open Orphan PLC - London-based pharmaceutical services - For 2021, expects to report earnings before interest, tax, depreciation and amortisation, on revenue which is set to be GBP40 million, up from GBP20.6 million in 2020. For 2022, the company is targeting GBP50 million in non-Covid work revenue. Read More

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

24th Feb 2022 14:48

Open Orphan PLC - London-based pharmaceutical services - Moves Non-Executive Director Mo Khan to chief executive officer, effective immediately. Khan had joined the Open Orphan board back in October. The company notes he has 25 years of clinical research experience. Cathal Friel remains executive chair, while Open Orphan will aim to find a new independent non-executive director within the next six months. Read More

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

22nd Feb 2022 21:57

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: Positive results from Open Orphan human challenge study

17th Feb 2022 20:13

Open Orphan PLC - pharmaceutical services provider - Sees positive results from a human challenge study assessing its respiratory syncytial virus antiviral candidate, EDP-938. Says results from the study have been published in The New England Journal of Medicine. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a, double-blind, placebo-controlled trial. Read More

FTSE 100 Latest

Value8,809.74

Change53.53